NFlection Therapeutics is a biotechnology company specializing in the discovery and development of targeted therapies for rare disorders caused by aberrant activation of the RAS pathway, known as RASopathies. Our primary focus is on addressing cutaneous neurofibromas in neurofibromatosis type 1, as well as disfiguring congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous, and squamous cell carcinoma induced by immunosuppressants. With funding from venBio and F-Prime Capital, we have assembled a team of experienced drug development professionals and key opinion leaders who are dedicated to developing a safe and effective soft topical MEK inhibitor for treating these disfiguring conditions.

At NFlection, our mission is to provide patients with a non-surgical treatment option that is both safe and effective